OJU  Vol.5 No.12 , December 2015
Prevalence of Isolated “Pre-Malignant” Lesions on Prostate Biopsy in a Racially Diverse Community Screened Cohort
Abstract: Objective: We investigated rates of prostate cancer (PCa), high-grade prostatic intraepithelial neoplaisa (HGPIN) and atypical small acinar proliferation (ASAP) in a multiethnic cohort. Methods: We evaluated prostate biopsy outcomes in men enrolled in the San Antonio Center of Biomarkers of Risk for prostate cancer (SABOR) prospective, observational study. PCa-free men underwent annual PSA testing over nearly 14 years with biopsies based on community standards. We investigated biopsy outcomes with a special interest in rates of cancer, HGPIN, and ASAP. Results: We identified 975 prostate biopsies in 801 subjects from 3/1/2001 to 1/9/2014. PCa, HGPIN, or ASAP was encountered in 28.8% (281/975), 10.1% (98/975), and 5.2% (51/975) of prostate biopsy specimens, respectively. The most significant risk factor for a PCa diagnosis was African American race (OR 5.0, 95% CI: 2.2 - 11.4, p < 0.001). HGPIN and ASAP occurred more commonly in association with PCa (both p < 0.001). We identified 57% (24/42) of men diagnosed with a “pre-malignant” lesion on prostate biopsy and had a subsequent biopsy. Of those only 8% (2/24) were diagnosed with prostate cancer (both Gleason 3 + 3) within 1 year of the initial biopsy. Conclusion: We note a 5-fold increased risk of PCa for African American men. The incidence of HGPIN and ASAP are consistent with previously reported incidence. If diagnosed in isolation, repeat biopsy within one year could be delayed or eliminated as it may not change prostate cancer outcomes.
Cite this paper: A. Liss, M. , Ankerst, D. , Zapata, D. , Hernandez, J. , Leach, R. and Thompson, I. (2015) Prevalence of Isolated “Pre-Malignant” Lesions on Prostate Biopsy in a Racially Diverse Community Screened Cohort. Open Journal of Urology, 5, 213-219. doi: 10.4236/oju.2015.512034.

[1]   Siegel, R.L., Miller, K.D. and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29.

[2]   Seltzer, M.A., Shinohara, K., Bhargava, V., Carroll, P.R. and Presti Jr., J.C. (1996) Comparison of Systematic Sextant and Lesion Directed Biopsies in Prostate Cancer Detection. Urologic Oncology, 2, 136-138.

[3]   Welch, H.G., Fisher, E.S., Gottlieb, D.J. and Barry, M.J. (2007) Detection of Prostate Cancer via Biopsy in the Medicare-SEER Population during the PSA Era. Journal of the National Cancer Institute, 99, 1395-1400.

[4]   Kapoor, D.A., Bostwick, D.G., Mendrinos, S.E., Anderson, A.E. and Olsson, C.A. (2013) Utilization Trends and Positive Biopsy Rates for Prostate Biopsies in the United States: 2005 to 2011. Reviews in Urology, 15, 137-144.

[5]   Patel, A.R. and Jones, J.S. (2009) Optimal Biopsy Strategies for the Diagnosis and Staging of Prostate Cancer. Current Opinion in Uurology, 19, 232-237.

[6]   Fowler Jr., J.E., Bigler, S.A. and Farabaugh, P.B. (2002) Prospective Study of Cancer Detection in Black and White Men with Normal Digital Rectal Examination but Prostate Specific Antigen Equal or Greater than 4.0 ng/mL. Cancer, 94, 1661-1667.

[7]   Mullins, C.D., Onukwugha, E., Bikov, K., Seal, B. and Hussain, A. (2010) Health Disparities in Staging of SEER-Medicare Prostate Cancer Patients in the United States. Urology, 76, 566-572.

[8]   Epstein, J.I. and Herawi, M. (2006) Prostate Needle Biopsies Containing Prostatic Intraepithelial Neoplasia or Atypical Foci Suspicious for Carcinoma: Implications for Patient Care. The Journal of Urology, 175, 820-834.

[9]   Gomez, P., Manoharan, M., Sved, P., Kim, S.S. and Soloway, M.S. (2004) Radical Retropubic Prostatectomy in Hispanic Patients. Cancer, 100, 1628-1632.

[10]   Siege, R., Ma, J., Zou, Z. and Jemal, A. (2014) Cancer Statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 9-29.

[11]   Pinsky, P.F., Ford, M., Gamito, E., et al. (2008) Enrollment of Racial and Ethnic Minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Journal of the National Medical Association, 100, 291-298.

[12]   Weinstein, M.H., Greenspan, D.L. and Epstein, J.I. (1998) Diagnoses Rendered on Prostate Needle Biopsy in Community Hospitals. The Prostate, 35, 50-55.<50::AID-PROS7>3.0.CO;2-L

[13]   Thompson Jr., I.M., Leach, R.J. and Ankerst, D.P. (2014) Focusing PSA Testing on Detection of High-Risk Prostate Cancers by Incorporating Patient Preferences into Decision Making. JAMA, 312, 995-996.

[14]   Ploussard, G., Plennevaux, G., Allory, Y., et al. (2009) High-Grade Prostatic Intraepithelial Neoplasia and Atypical Small Acinar Proliferation on Initial 21-Core Extended Biopsy Scheme: Incidence and Implications for Patient Care and Surveillance. World Journal of Urology, 27, 587-592.

[15]   Brausi, M., Castagnetti, G., Dotti, A., De Luca, G., Olmi, R. and Cesinaro, A.M. (2004) Immediate Radical Prostatectomy in Patients with Atypical Small Acinar Proliferation. Over Treatment? The Journal of Urology, 172, 906-908.

[16]   Feneley, M.R., Green, J.S., Young, M.P., et al. (1997) Prevalence of Prostatic Intra-Epithelial Neoplasia (PIN) in Biopsies from Hospital Practice and Pilot Screening: Clinical Implications. Prostate Cancer and Prostatic Diseases, 1, 79-83.

[17]   Gupta, C., Ren, J.Z. and Wojno, K.J. (2004) Individual Submission and Embedding of Prostate Biopsies Decreases Rates of Equivocal Pathology Reports. Urology, 63, 83-86.

[18]   Thompson, I.M., Ankerst, D.P., Chi, C., et al. (2006) Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 98, 529-534.

[19]   Ankerst, D.P., Hoefler, J., Bock, S., et al. (2014) Prostate Cancer Prevention Trial Risk Calculator 2.0 for the Prediction of Low-vs High-Grade Prostate Cancer. Urology, 83, 1362-1367.